Mizuho on Apogee Therapeutics Inc (APGE): data shows potential 'best-in-indication biologic efficacy and convenience'
Tweet Send to a Friend
Mizuho analyst Joseph Catanzaro reiterated an Outperform rating and $105.00 price target on Apogee Therapeutics Inc (NASDAQ: APGE)The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
